相关实验视频

Updated: Jul 1, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

一个G6PC2抑制剂的生物化学和代谢表征

Emily M Hawes¹, Mohsin Rahim², Zeinab Haratipour³

¹Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.

|March 2, 2024

概括

一种新的抑制剂,VU0945627,选择性地准人体葡萄糖-6-酸酶催化子单元2 (G6PC2) 以降低禁食血糖 (FBG). 这种化合物还抑制葡萄糖-6-酸盐输送体SLC37A4,有可能预防糖尿病和癌症.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
代谢疾病代谢疾病

背景情况:

有三种葡萄糖-6-酸酶催化子单元 (G6PC1-3) 存在,其中G6PC1和G6PC2调节禁食血糖 (FBG).
增加的FBG与2型糖尿病和癌症有关,使G6PC1和G6PC2抑制剂成为潜在的预防剂.

研究的目的:

描述一种新的G6PC2抑制剂,VU0945627,并评估其降低FBG的潜力.
研究VU0945627.7的异型特异性和作用机制.

主要方法:

对人类和小鼠G6PC异型的酶抑制试验.
使用PyRx和AlphaFold2结构模型进行虚拟对接.
现场定向的突变发生研究.
在βTC-3细胞和小鼠肝脏显微体中抑制葡萄糖循环.

主要成果:

VU0945627优先抑制人类G6PC2而不是G6PC1,并激活G6PC3.
它作为G6PC2的混合抑制剂,改变Km和Vmax.
由于特定的残留物差异,VU0945627不会抑制小鼠G6PC2.
该化合物还通过向SLC37A4载体来抑制小鼠细胞中的葡萄糖循环.

结论:

VU0945627是人类G6PC2的选择性抑制剂,具有潜在的治疗应用.
它对G6PC2和SLC37A4的双重抑制值得进一步研究以预防代谢性疾病.
了解物种特异性抑制对于开发向G6PC抑制剂至关重要.

关键词:

酶抑制可以抑制酶.禁食的血糖禁食的血糖葡萄糖-6-酸盐酶是什么小岛是一个小岛.

更多相关视频

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...